Articles > Popular publications > PR Newswire press releases > October-December 2009 > Friday, November 6

Article: NeurogesX Reports Third Quarter 2009 Results.

Article from:
PR Newswire
Article date:
November 6, 2009
Copyright

Conference Call Today at 9am ET

SAN MATEO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- 

 
  3Q09 Corporate Highlights: 
  --  Completed transfer of Qutenza(TM) E.U. Marketing Authorization to 
  Astellas Pharma Europe Ltd. 
  --  Made significant progress in commercial readiness activities 
  --  Expanded management team to include VP Sales; Senior Director, 
  Marketing; and Director, Commercial Operations 
 
  --  Appointed Bradford S. Goodwin to board as director and Audit Committee 
  chairman 
 
  Upcoming 2009 Milestones: 
 
  --  FDA PDUFA date November 16, 2009 for Qutenza NDA to manage pain 
  associated with PHN

NeurogesX, Inc. ... 







Read all of this article with a FREE trial
















Related newspaper, magazine, and journal articles:









  




 

    

 
 
   
 


   
  
  Article: United States: NeurogesX Receives European ...

  
  TendersInfo; 
  May 22, 2009 ;  
  
  
 
  700+ words
... ... formally granted marketing authorization of Qutenza(TM) 179 mg cutaneous patch (formerly ... with other medicinal products for pain. Qutenza can only be obtained with a prescription ... centralized marketing authorization allows Qutenza to be marketed in all 27 countries of ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) ...

  
  PR Newswire; 
  November 16, 2009 ;  
  
  
 
  700+ words
... ... organization. With Qutenza now approved both in the United States and European Union ... to commercialize Qutenza in the United States through its own ... approved in the United States for the management of PHN. Qutenza is designed to ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: NeurogesX Announces Publication of Phase 3 Data for ...

  
  PR Newswire; 
  January 12, 2009 ;  
  
  
 
  700+ words
... ... a long duration of effect, Qutenza acts locally, at the pain ... subsequent commercial launches of Qutenza in both the United States and European Union." The ... from the Phase 3 C116 study of Qutenza in patients with PHN showed ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: NeurogesX Announces Publication of Phase 3 Data for ...

  
  Clinical Trials Week; 
  January 26, 2009 ;  
  
  
 
  700+ words
... ... a long duration of effect, Qutenza acts locally, at the pain ... subsequent commercial launches of Qutenza in both the United States and European Union." The ... from the Phase 3 C116 study of Qutenza in patients with PHN showed ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: NeurogesX Announces New PDUFA Date for Qutenza(TM) New ...

  
  PR Newswire; 
  August 5, 2009 ;  
  
  
 
  700+ words
... ... announced that the United States Food and Drug ... NDA) for Qutenza(TM) to manage ... of launching Qutenza in the United States in the first ... products for pain. Qutenza will be marketed ... Ltd. In the United States, NeurogesX ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: NeurogesX Announces New PDUFA Date for Qutenza™ New ...

  
  Biotech Week; 
  August 19, 2009 ;  
  
  
 
  581 words
... ... therapies, announced that the United States Food and Drug Administration ... new drug application (NDA) for Qutenza™ to manage pain ... goal of launching Qutenza in the United States in the first half of 2010." Keywords ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: NeurogesX and Astellas Enter Commercialization Agreement for ...

  
  PR Newswire Europe; 
  June 22, 2009 ;  
  
  
 
  700+ words
... ... agreement for the commercialization of Qutenza(TM) in the European Economic Area ... s approval received in May 2009, of Qutenza (capsaicin 179 mg) cutaneous patch for ... agreement, Astellas will commercialize Qutenza in the above-mentioned territories and ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: NeurogesX Receives European Commission Approval for ...

  
  PR Newswire; 
  May 21, 2009 ;  
  
  
 
  700+ words
... ... formally granted marketing authorization of Qutenza(TM) 179 mg cutaneous patch (formerly ... with other medicinal products for pain. Qutenza can only be obtained with a prescription ... centralized marketing authorization allows Qutenza to be marketed in all 27 countries of ... 







   
 

























 



 





 






Newsweek
Harper's Magazine
The Washington Post
Chicago Tribune
Crain's Chicago Business
PRNewswire
Pediatric News
The Nation
Advertising Age
The Economist (US)
A FREE trial gives you access to over 80 million articles!
Access over 6,500 publications with a FREE trial!


  



Find articles, research, and archives